SuperGen, Inc. (SUPG)

Well heeled, financially...a comfortable moat...provides lots of room for R&D without feeling the pinch. Management appears to have built and strong model for developing cancer and related therapies that cover a broad spectrum of life-threatening diseases. I originally bought in at $2.22 and will give it several years. Who knows...maybe a buyout is down the line, as well.

A well capitalized bio tech company with potential that's trading not much more than its cash per share.

Alot of insider buying. when i found "jazz" it was around 2$ with alot of insider buying. jazz went to 9$ in the next 3 months

lots of cash, pipeline with good potential

Lots of Insider buying here..... SuperGen is a pharmaceutical company whose mission is to prolong, improve the quality of and ultimately, save the lives of those people afflicted with life-threatening diseases, especially cancer.
The company possesses a broad portfolio of proprietary cancer therapies that target a variety of solid tumors, hematological malignancies and blood disorders, offering renewed hope to patients who suffer from these illnesses.
The company is led by a seasoned management team with extensive experience in all aspects of the oncology pharmaceutical industry. TS

portefeuille

They have significant cash and cash flow to enable the development of their pipeline of drug candidates. They are a significant buyout possibility.

great pipeline. bought at 2.01 with real money

Has some great research in the cancer field. Has become more financially focused. Products in pipeline very promising. Should take off from here.

I lost my bet that Dacogen would show a survival benefit similar to Vidaza. I find the rebound in Supergen stock inexplicable given an absence of positive catalysts. I expect that losses will continue to widen as Dacogen loses market share and the company is forced to expend more resources on their anemic pipeline.

Ongoing revenue to operate with while new drugs are developed. Speculation with cash on board.

A cancer biotech stock trading for near cash with zero debt with pending EORTC survival data due shortly for Dacogen likley to support EU marketing application by JNJ. Dacogen is already apporved in USA and SUPG has a robust, early-stage cancer piepline and discovery platform in place.

At bottom price NO dept royalty income,pe low why not.

Has been looking kind of doggey but there are events to be disclosed.

According to Nasdaq:

1 - Underperform

3 - Hold

3 - Buy

The 12 month consensus is $10. Looks good to me!

Stock should rebound over the short-term.

The strong pipeline of marketable products

Good stock all around. 1 year target is $10. It's a penny stock, so it's risky, but I'm willing to risk that for 150% profit in a year.

An immature idiot like myself can't not rate a stock tickered "SUPG" an outperformer.